Hutchmed China trades 0.98 percent higher on Monday 26th of October
Hutchmed China shares rise 0.98% as AstraZeneca’s gastric‑cancer antibody shows 5‑month survival boost, driving investor interest.
3 minutes to read
HUTCHMED CHINA
Hutchmed China’s GSK Deal Sparks New Growth Trajectory in Oncology
Hutchmed China teams with GSK to launch the dual‑target antibody HMPL‑A830, opening up a $1 bn+ revenue path and boosting its oncology pipeline worldwide.
3 minutes to read
Hutchmed China Rises 4% on GSK Licensing Deal, Boosting Oncology Outlook
Hutchmed China’s stock climbs 4.13% after securing an exclusive GSK licensing deal for HMPL‑A830, boosting its precision‑oncology pipeline and investor confidence.
3 minutes to read
Hutchmed China (0013.HK) Soars 3.92% – 24‑Hour Market Snapshot & Peer Insights
Hutchmed China (0013.HK) surged 3.92% to HKD 23.20, trading 130.8M HKD in volume, with a market cap of HKD 19.4B—key metrics for investors.
2 minutes to read